USA - engelska - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa and levodopa extended-release tablets, usp are indicated  in  the  treatment  of  parkinson’s  disease,  post-encephalitic  parkinsonism,  and  symptomatic  parkinsonism  that  may  follow  carbon  monoxide  intoxication  or  manganese  intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets. these  inhibitors  must  be  discontinued  at  least  two  weeks  prior  to  initiating  therapy  with  carbidopa and levodopa extended-release tablets. carbidopa and levodopa extended-release tablets may  be  administered  concomitantly  with  the  manufacturer’s  recommended  dose  of  an  mao  inhibitor  with  selectivity  for  mao   type  b  (e.g.,  selegiline  hcl)  (see  precautions,  drug  interactions ). carbidopa and levodopa extended-release tablets are contraindicated in patients with known hypersensitivity to any component of this  drug, and  in  patients  with  narrow-angle  glaucoma.

USA - engelska - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate ointment usp, 0.05% is super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in pediatric patients under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. clobetasol propionate ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

USA - engelska - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide lotion is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. desonide lotion is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

USA - engelska - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - amantadine hydrochloride (unii: m6q1eo9td0) (amantadine - unii:bf4c9z1j53) - amantadine hydrochloride tablets  are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus. amantadine hydrochloride tablets  are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. influenza a prophylaxis amantadine hydrochloride tablets  are indicated for chemoprophylaxis against signs and symptoms of influenza a virus infection. because amantadine hydrochloride tablets do not completely prevent the host immune response to influenza a infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. following vaccination during an influenza a outbreak, amantadine hydrochloride tablets prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. influenza a treatment amantadine hydrochloride tablets  are also indicated in the treatment

USA - engelska - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - cyclobenzaprine hydrochloride (unii: 0ve05jys2p) (cyclobenzaprine - unii:69o5wqq5ti) - cyclobenzaprine hydrochloride tablets, usp is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. cyclobenzaprine hydrochloride, tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. cyclobenzaprine hydrochloride tablets has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. hypersensitivity to any component of this product. concomitant use of monoamine oxidase (mao) inhibitors or

USA - engelska - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies). entacapone tablets effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end-of-dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

USA - engelska - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - prazosin hydrochloride (unii: x0z7454b90) (prazosin - unii:xm03yj541d) - prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and

USA - engelska - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - theophylline anhydrous (unii: 0i55128jyk) (theophylline anhydrous - unii:0i55128jyk) - theophylline anhydrous 300 mg - theophylline extended-release tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. theophylline extended-release tablets are contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.

USA - engelska - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - acyclovir (unii: x4hes1o11f) (acyclovir - unii:x4hes1o11f) - acyclovir ointment usp, 5% is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous herpes simplex virus infections in immunocompromised patients. acyclovir ointment 5% is contraindicated in patients who develop hypersensitivity to the components of the formulation.

USA - engelska - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate cream, usp is a super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in pediatric patients under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. clobetasol propionate cream usp, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.